Table of Content:
1. Introduction
1.1. Research Objective
1.2. Research Methodology
1.3. Research Process
1.4. Respondent Profile
2. Executive Summary
3. Global Biosimilars Market Outlook, 2019-2029F
3.1. Market Size & Analysis
3.2. Market Share & Analysis
3.2.1. By Molecule
3.2.1.1. Infliximab
3.2.1.2. Insulin Glargine
3.2.1.3. Epoetin Alfa
3.2.1.4. Etanercept
3.2.1.5. Filgrastim
3.2.1.6. Somatropin
3.2.1.7. Rituximab
3.2.1.8. Follitropin Alfa
3.2.1.9. Adalimumab
3.2.1.10 Pegfilgrastim
3.2.1.11 Trastuzumab
3.2.1.12 Bevacizumab
3.2.1.13 Others
3.2.2. By Indication
3.2.2.1. Auto-Immune Disease
3.2.2.2. Blood Disorder
3.2.2.3. Diabetes
3.2.2.4. Oncology
3.2.2.5. Growth Deficiency
3.2.2.6. Female Infertility
3.2.2.7. Others
3.2.3. By Manufacturing
3.2.3.1. In-house Manufacturing
3.2.3.2. Contract Manufacturing
3.2.4. By Region
3.2.4.1. Asia-Pacific
3.2.4.2. Europe
3.2.4.3. North America
3.2.4.4. Middle East & Africa
3.2.4.5. Latin America
4. Asia-Pacific Biosimilars Market Outlook, 2019-2029F
4.1. Market Size & Analysis
4.2. Market Share & Analysis
4.2.1. By Molecule
4.2.2. By Indication
4.2.3. By Manufacturing
4.2.4. By Country
4.2.4.1. China
4.2.4.2. India
4.2.4.3. Japan
4.2.4.4. South Korea
4.2.4.5. Australia
4.2.4.6. Rest of Asia-Pacific
5. Europe Biosimilars Market Outlook, 2019-2029F
5.1. Market Size & Analysis
5.2. Market Share & Analysis
5.2.1. By Molecule
5.2.2. By Indication
5.2.3. By Manufacturing
5.2.4. By Country
5.2.4.1. United Kingdom
5.2.4.2. Germany
5.2.4.3. France
5.2.4.4. Italy
5.2.4.5. Russia
5.2.4.6. Rest of Europe
6. North America Biosimilars Market Outlook, 2019-2029F
6.1. Market Size & Analysis
6.2. Market Share & Analysis
6.2.1. By Molecule
6.2.2. By Indication
6.2.3. By Manufacturing
6.2.4. By Country
6.2.4.1. United States
6.2.4.2. Canada
7. Latin America Biosimilars Market Outlook, 2019-2029F
7.1. Market Size & Analysis
7.2. Market Share & Analysis
7.2.1. By Molecule
7.2.2. By Indication
7.2.3. By Manufacturing
7.2.4. By Company
7.2.4.1. Brazil
7.2.4.2. Mexico
7.2.4.3. Rest of Latin America
8. Middle East & Africa Biosimilars Market Outlook, 2019-2029F
8.1. Market Size & Analysis
8.2. Market Share & Analysis
8.2.1. By Molecule
8.2.2. By Indication
8.2.3. By Manufacturing
8.2.4. By Company
8.2.4.1. Saudi Arabia
8.2.4.2. UAE
8.2.4.3. South Africa
8.2.4.4. Rest of Middle East and Africa
9. Global Biosimilars Market Dynamics
9.1. Growth Drivers
9.2. Challenges
9.3. Impact Analysis
10. Global Biosimilars Market Opportunities
11. Global Biosimilars Value Chain Analysis
12. Global Biosimilars Market Policies and Regulations
13. Global Biosimilars Market Trends & Insights
15. Global Biosimilars Market Porter's Five Forces Analysis
15. Global Biosimilars Market-Entropy
15.1. New Product Launches
15.2. M&A, Collaborations, JVs, and Partnerships
16. Global Biosimilars Market Company Analysis
16.1. Novartis AG
16.2. Pfizer Inc.
16.3. Amgen Inc.
16.5. Coherus Biosciences Inc.
16.5. Mylan NV (Viatris Inc.)
16.6. Samsung Bioepis Co. Ltd
16.7. Pfizer Inc.
16.8. Eli Lilly & Company
16.9. Dr. Reddy?s Laboratories
16.10. Biocad
17. About Us & Contact Details